Clinical Trial Update: Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia [Phase 2]

View source ↗

Summary

Phase 2 study investigating higher doses of daptomycin and vancomycin for MRSA bacteremia/endocarditis was terminated with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endocarditis
• Infective Endocarditis

Drugs mentioned

• Daptomycin (daptomycin)
• Vancomycin (vancomycin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Endocarditis, Bacterial, Infective Endocarditis | Phase 2 | Status: TERMINATED | Results posted: 2011-12-06